Insider Transactions in Q1 2022 at Opiant Pharmaceuticals, Inc. (OPNT)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 27
2022
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,995
-2.48%
|
$51,870
$26.15 P/Share
|
|
Jan 27
2022
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,518
-6.33%
|
$39,468
$26.19 P/Share
|
|
Jan 10
2022
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,058
-1.3%
|
$31,740
$30.49 P/Share
|
|
Jan 10
2022
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
385
-1.58%
|
$11,550
$30.49 P/Share
|
|
Jan 10
2022
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
432
-1.2%
|
$12,960
$30.6 P/Share
|
|
Jan 04
2022
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+32.91%
|
-
|
|
Jan 04
2022
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+29.27%
|
-
|
|
Jan 04
2022
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+26.32%
|
-
|
|
Jan 04
2022
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+37.93%
|
-
|
|
Jan 04
2022
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.99%
|
-
|
|
Jan 04
2022
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+33.01%
|
-
|